[1]
R. LeBlanc, S. Hollmann, and J. Tay, “CANADIAN COST ANALYSIS COMPARING MAINTENANCE THERAPY WITH BORTEZOMIB VERSUS LENALIDOMIDE FOR PATIENTS WITH MULTIPLE MYELOMA POST AUTOLOGOUS STEM CELL TRANSPLANT”, J Popl Ther Clin Pharmacol, vol. 23, no. 1, Nov. 2018.